| Summary of Computation of Company's Basic and Diluted Net Loss per Share |
The following table sets forth the computation of the Company’s basic and diluted net loss per share.
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
|
2020
|
|
|
2019
|
|
|
2020
|
|
|
2019
|
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss), basic and diluted
|
|
$
|
17,139
|
|
|
$
|
(12,912
|
)
|
|
$
|
27,416
|
|
|
$
|
(40,955
|
)
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares used to compute basic EPS
|
|
|
36,887,266
|
|
|
|
22,946,989
|
|
|
|
29,994,917
|
|
|
|
22,913,118
|
|
|
Dilutive effect of common stock options
|
|
|
828,623
|
|
|
|
–
|
|
|
|
228,557
|
|
|
|
–
|
|
|
Dilutive effect of restricted stock units
|
|
|
159,788
|
|
|
|
–
|
|
|
|
120,649
|
|
|
|
–
|
|
|
Dilutive effect of warrants to purchase common stock
|
|
|
1,875
|
|
|
|
–
|
|
|
|
5,733
|
|
|
|
–
|
|
|
Weighted-average shares used to compute diluted EPS
|
|
|
37,877,552
|
|
|
|
22,946,989
|
|
|
|
30,349,856
|
|
|
|
22,913,118
|
|
|
Net income (loss) earnings per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.46
|
|
|
$
|
(0.56
|
)
|
|
$
|
0.91
|
|
|
$
|
(1.79
|
)
|
|
Diluted
|
|
$
|
0.45
|
|
|
$
|
(0.56
|
)
|
|
$
|
0.90
|
|
|
$
|
(1.79
|
)
|
|
| Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share |
The following common stock equivalents were excluded from the computation of diluted net loss per share for the period ended September 30, 2019, because including them would have been antidilutive:
|
|
As of September 30,
|
|
|
|
|
2019
|
|
|
Common stock options issued and outstanding
|
|
|
3,977,783
|
|
|
Restricted stock units issued and outstanding
|
|
|
340,687
|
|
|
Warrants to purchase common stock
|
|
|
71,813
|
|
|
Total
|
|
|
4,390,283
|
|
|